CN104940823B - Scutellaria baicalensis-scutellaria baicalensis mixture for treating B cell lymphoma and application thereof - Google Patents
Scutellaria baicalensis-scutellaria baicalensis mixture for treating B cell lymphoma and application thereof Download PDFInfo
- Publication number
- CN104940823B CN104940823B CN201510364639.2A CN201510364639A CN104940823B CN 104940823 B CN104940823 B CN 104940823B CN 201510364639 A CN201510364639 A CN 201510364639A CN 104940823 B CN104940823 B CN 104940823B
- Authority
- CN
- China
- Prior art keywords
- treatment
- group
- cell
- ancient books
- reed mentioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000003950 B-cell lymphoma Diseases 0.000 title claims abstract description 9
- 241000207929 Scutellaria Species 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 251
- 239000003814 drug Substances 0.000 claims abstract description 44
- 238000002512 chemotherapy Methods 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 13
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 12
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 12
- 235000013976 turmeric Nutrition 0.000 claims abstract description 12
- 235000010674 Prunella vulgaris Nutrition 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 238000009104 chemotherapy regimen Methods 0.000 claims description 5
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 238000002648 combination therapy Methods 0.000 claims description 3
- 244000008991 Curcuma longa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 210000004027 cell Anatomy 0.000 abstract description 34
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 30
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract description 15
- 244000163122 Curcuma domestica Species 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 3
- 231100000226 haematotoxicity Toxicity 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 235000014676 Phragmites communis Nutrition 0.000 description 99
- 238000000540 analysis of variance Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 238000000546 chi-square test Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 9
- 230000007681 cardiovascular toxicity Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000002146 bilateral effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010061188 Haematotoxicity Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- -1 liver protection Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to aThe traditional Chinese medicine composition for treating B cell lymphoma is prepared from the following raw material medicines of scutellaria baicalensis, selfheal, turmeric and astragalus mongholicus, and has the advantages of increasing the curative effect of treating high-risk D L BC L in the early stage of R-CHOP scheme treatment, achieving complete remission earlier, improving the CR rate of patients with poor overall functional state KPS, relieving the toxic and side effects of chemotherapy, particularly non-hematologic toxicity, and treating CD3+CD4+T cell, CD4+CD28+The cell has protective effect and can increase CD4+/CD8+Cell ratio.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, specifically, being a kind of a kind of reed mentioned in ancient books Huang mixture for treating B cell lymphoma and its answering
With.
Background technology
Malignant lymphoma (Malignant Lymphoma, ML) is to be primary in lymph node or tie the pernicious of perilymph tissue to swell
Tumor.According to, whether there is or not inner-this cell (Reed-Sternberg Cell, R-S cells) or its anomaly, being divided into pathology：Huo Qi
Golden lymthoma (Hodgkin Lymphoma, HL) and non-Hodgkin lymphoma (non-Hodgkin Lymphoma, NHL).At me
State NHL accounts for 80-90%, and lymthoma incidence male is 1.39/10 ten thousand, and women is 0.84/10 ten thousand, and the death rate is 1.5/10 ten thousand,
And U.S. HL accounts for 25%.In past 30 years, the incidence of NHL is increased with annual 4% speed, worldwide several
Increase one times.In recent years, the incidence of China's malignant lymphoma also presents a rapidly rising trend, and has become most common ten
One of big malignant tumour.
Diffusivity large B cell lymphoid tumor (Diffuse Large B-cell Lymphoma, DLBCL) is most common
NHL accounts for about initial every year 30.6%.In China, DLBCL incidences account for about the 40-50% of adult's new cases.
The cause of disease of malignant lymphoma is still not clear.Lasting virus infection and immune deficiency may be the weight that lymthoma occurs
Want factor.
DLBCL high-risk invasion NHL in belonging to, progression of disease is rapid, and recurrence is easy after treatment.Lymphoma treating is still at present
Based on classic chemotherapy method, offer limited effectiveness, and it is often accompanied by more serious toxic side effect, and may cause to treat associated tumors
Generation, these may influence the therapeutic effect and long term survival of Lymphoma.Use routinizing for anthracycline-containing drug
The patient for treating only 40% obtains long-term remission.In recent years, anti-CD-20 monoclonal antibody rituximab (Rituximab) although application
The clinical efficacy of DLBCL is further improved, but still is recurred rapidly after having 30-40% patient for treatment invalid or treatment, in advance
It is poor afterwards.Need safety and low toxicity effective treatment means and drug.
It is now recognized that lymthoma is the malignant tumour of one group of different pathological types and different clinical behaviors, it is various to have respectively
Characteristic molecular biology changes.Cell cycle regulating and abnormal apoptosis play an important role in the morbidity of lymthoma.
More and more evidences show the main reason for apoptosis defect is many B cell lymphoma morbidities and chemotherapy resistance.It interferes spontaneous
Property cells survival signal path and it is apoptosis-induced be have become treatment lymthoma a kind of new strategies.It is thin for lympha tumour
The research and development of the targeted drug of cellular surface antigen, intracellular signal transduction access and cell micro-environment have made great progress.
Recently, more and more studies have shown that many natural traditional Chinese medicine ingredients and preparation have inducing apoptosis of tumour cell
Effect.Chinese medicine natural component and small compound preparation have had by experiment and clinical research confirmation in blood disease field very wide
Wealthy application prospect.As to be clinically used for acute progranulocyte white for arsenic trioxide and Chinese medicine compound oral preparation compound realgar natural indigo tablet
Blood disease (acute promyelocytic leukemia, APL) is treated successful etc..Still lack class in lymphoma treating field
Like drug.
Invention content
The purpose of the present invention is being directed to deficiency in the prior art, a kind of Chinese traditional medicine composition for treating B cell lymphoma is provided
Object.
Another purpose of the present invention is to provide a kind of application of Chinese medicine composition that treating B cell lymphoma.
To achieve the above object, the technical solution adopted by the present invention is that：A kind of Chinese medicine composition for treating lymthoma, it is described
Chinese medicine composition be made of following bulk pharmaceutical chemicals：Radix scutellariae, Prunella vulgaris, turmeric, Radix Astragali.
The Chinese medicine composition is made of the bulk pharmaceutical chemicals of following parts by weight：1-3 parts of radix scutellariae, 0.5-1.5 parts of Prunella vulgaris, ginger
0.5-1.5 parts yellow, 1-3 parts of Radix Astragali.
The Chinese medicine composition is made of the bulk pharmaceutical chemicals of following parts by weight：1.8-2.2 parts of radix scutellariae, Prunella vulgaris 0.9-1.1
Part, 0.9-1.1 parts of turmeric, 1.8-2.2 parts of Radix Astragali.
The Chinese medicine composition is made of the bulk pharmaceutical chemicals of following parts by weight：2 parts of radix scutellariae, 1 part of Prunella vulgaris, 1 part of turmeric, Huang
2 parts of stilbene.
The Chinese medicine composition and R-CHOP chemotherapy regimens or CHOP chemotherapy regimen combination therapies.
To realize above-mentioned second purpose, the technical solution adopted by the present invention is that：The Chinese medicine composition is controlled in preparation
Treat the application in the drug of lymthoma.
The lymthoma is non-Hodgkin lymphoma.
The lymthoma is B cell lymphoma.
The lymthoma is diffusivity large B cell lymphoid tumor.
The invention has the advantages that：
1, Chinese medicine composition (a kind of reed mentioned in ancient books Huang mixture) of the invention increase R-CHOP Regimen Chemotherapies it is initial in high-risk DLBCL treatment
Effect, obtains complete incidence graph earlier.
2, a kind of reed mentioned in ancient books Huang mixture improves the CR rates of the poor patients of allomeric function state KPS.
3, a kind of reed mentioned in ancient books Huang mixture alleviates the toxicity of chemotherapy, especially non-blood toxicity.
4, a kind of reed mentioned in ancient books Huang mixture is to CD3+CD4+T cell, CD4+CD28+Cell has protective effect, improves CD4+/CD8+Cell ratio
Value.
Description of the drawings
Attached drawing 1-1：A kind of reed mentioned in ancient books Huang group is compared with control group intermediate period treatment reactivity
Note：* a kind of reed mentioned in ancient books Huang group is compared with control group mid-term effects, and Mann-Whitney U are examined, Z=-2.258, accurate notable
Property (bilateral) P=0.028, P ＜ 0.05.
Attached drawing 1-2：A kind of reed mentioned in ancient books Huang group is compared with control group final period therapeutic response rate
Note：* a kind of reed mentioned in ancient books Huang group is compared with control group final period curative effect, and Mann-Whitney U are examined, Z=-2.072, asymptotic notable
Property (bilateral) P=0.038, P ＜ 0.05.
Attached drawing 1-3：Mid-term and final assessment, a kind of reed mentioned in ancient books Huang group is compared with control group CR rates
Note：A kind of reed mentioned in ancient books Huang group is compared with control group CR rates, * mid-term effects, through chi-square analysis, χ2=4.986, p=0.033；
# final period curative effects, through chi-square analysis, χ2=4.477, p=0.044, P ＜ 0.05.
Attached drawing 1-4：A kind of reed mentioned in ancient books Huang group is compared with control group Kanofsky scoring layering CR rates
Note：* Kanofsky scorings 70+80 divides patient, a kind of reed mentioned in ancient books Huang group CR rates 95.7% (22/23) to be higher than control group 73.1%
(19/26), through Chi-square Test, χ2=4.553, p=0.033, P ＜ 0.05.
Attached drawing 1-5：A kind of reed mentioned in ancient books Huang group is compared with the pretherapy and post-treatment KPS variation degree of control group
Note 1：KPS=Karnofsky (Cattell, KPS, percentage) functional status standards of grading.It is to improve to increase by 10 points of persons,
Reduce by more than 10 points for deteriorate, increase or decrease≤10 points for stablize.
2：A kind of reed mentioned in ancient books Huang group compared with the control group, χ2=6.556, p=0.037, P ＜ 0.05.
Attached drawing 2-1 a kind of reed mentioned in ancient books Huang groups and CD3 in control group therapeutic process+Cell absolute value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD3+T cell absolute counting, treatment preceding 1119.06 ± 521.46,787.79 in treatment ±
337.73,821.68 ± 492.40 after treatment, Analysis of variance, in treatment compared with before treatment p=0.007, after treatment with control
Compare p=0.017, p ＜ 0.05 before treating；
B. control group CD3+T cell absolute counting, treatment preceding 908.14 ± 399.17,752.37 ± 286.33 in treatment,
760.09 ± 231.79 after treatment, Analysis of variance, in treatment compared with before treatment p=0.065, after treatment compared with before treatment
P=0.065, p ＞ 0.05；
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, after treatment.
Attached drawing 2-2：A kind of reed mentioned in ancient books Huang group and CD3 in control group therapeutic process+Cell relative value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD3+T cell relative value (%), treatment preceding 68.34 ± 12.47,77.54 ± 10.43 in treatment,
76.62 ± 10.77 after treatment, Analysis of variance, in treatment compared with before treatment p=0.001, after treatment compared with before treatment p
=0.004, p ＜ 0.05；
B. control group CD3+T cell relative value (%), treatment preceding 70.64 ± 12.66,78.74 ± 8.18 in treatment, treatment
Afterwards 75.98 ± 10.37, Analysis of variance, in treatment compared with before treatment p=0.003, after treatment compared with before treatment p=
0.05, p ＜ 0.05；
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, after treatment.
Attached drawing 2-3：A kind of reed mentioned in ancient books Huang group and CD3 in control group therapeutic process+CD4+Cell absolute value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD3+CD4+T cell absolute counting, treatment preceding 614.03 ± 353.05,396.06 in treatment ±
212.55,366.29 ± 178.75 after treatment, Analysis of variance, in treatment compared with before treatment p=0.011, after treatment with control
Compare p=0.002, p ＜ 0.05 before treating；
B. control group CD3+CD4+T cell absolute counting, treatment preceding 532.31 ± 285.50,345.07 in treatment ±
154.65,322.53 ± 139.36 after treatment, Analysis of variance, in treatment compared with before treatment p=0.011, after treatment with control
Compare p=0.003, p ＜ 0.05 before treating；
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, after treatment.
Attached drawing 2-4：A kind of reed mentioned in ancient books Huang group and CD3 in control group therapeutic process+CD4+Cell relative value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD3+CD4+T cell relative value (percentage, %), treatment preceding 36.66 ± 10.07, in treatment
38.26 ± 9.88,36.05 ± 9.06 after treatment, Analysis of variance, in treatment compared with before treatment p=0.505, after treatment with
Compare p=0.364, p ＞ 0.05 before treatment；
B. control group CD3+CD4+T cell relative value (percentage, %), treatment preceding 40.36 ± 12.55,38.93 in treatment
± 13.29,32.43 ± 10.32 after treatment, Analysis of variance, in treatment compared with before treatment p=0.644, p ＞ 0.05；Treatment
The p=0.034 compared with before treatment afterwards, p ＜ 0.05.
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, after treatment.
Attached drawing 2-5：A kind of reed mentioned in ancient books Huang group and CD3 in control group therapeutic process+CD8+Cell absolute value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD3+CD8+Absolute counting, treatment preceding 439.52 ± 325.63,340.76 ± 161.89 in treatment,
406.29 ± 337.43 after treatment, Analysis of variance, in treatment compared with before treatment p=0.163, after treatment compared with before treatment
P=0.643, p ＞ 0.05；
B. control group CD3+CD8+Absolute counting, treatment preceding 321.79 ± 165.08,359.19 ± 208.86 in treatment, is controlled
386.69 ± 155.18 after treatment, Analysis of variance, in treatment compared with before treatment p=0.43, after treatment compared with before treatment p=
0.155, p ＞ 0.05；
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, after treatment.
Attached drawing 2-6：A kind of reed mentioned in ancient books Huang group and CD3 in control group therapeutic process+CD8+Cell relative value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD3+CD8+T cell relative value (percentage, %), treatment preceding 26.44 ± 10.55, in treatment
33.99 ± 9.51,34.45 ± 10.34 after treatment, Analysis of variance, in treatment compared with before treatment p=0.003, after treatment with
Compare p=0.002, p ＜ 0.05 before treatment；
B. control group CD3+CD8+T cell relative value (percentage, %), treatment preceding 25.82 ± 12.18,35.43 in treatment
± 12.45,40.38 ± 11.47 after treatment, Analysis of variance, in treatment compared with before treatment p=0.003, after treatment with treatment
Preceding relatively p=0.000, p ＜ 0.05,
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, compare p=0.035 after treatment,
P ＜ 0.05.
Attached drawing 2-7：A kind of reed mentioned in ancient books Huang group and CD4 in control group therapeutic process+/CD8+Cell absolute counting ratio compares
Note：A. a kind of reed mentioned in ancient books Huang group CD4+/CD8+Cell absolute counting ratio, treatment preceding 1.67 ± 0.99,1.25 in treatment ±
0.62,1.12 ± 0.48 after treatment, Analysis of variance, in treatment compared with before treatment p=0.128, compare with before treatment after treatment
Compared with p=0.018, p ＜ 0.05；
B. control group CD4+/CD8+Cell absolute counting ratio, treatment preceding 2.06 ± 1.44,1.376 ± 0.98 in treatment,
0.98 ± 0.56 after treatment, Analysis of variance, in treatment compared with before treatment p=0.115, after treatment compared with before treatment p=
0.002, p ＜ 0.05；
C. it between two groups, is examined through independent sample T, compares p ＞ 0.05 before treatment, in treatment, after treatment.
Attached drawing 2-8：A kind of reed mentioned in ancient books Huang group and CD4 in control group therapeutic process+CD28+Cell relative value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD4+CD28+Cell relative value (percentage, %), treatment preceding 31.92 ± 9.99, in treatment
29.89 ± 9.41,28.95 ± 8.82 after treatment, Analysis of variance, in treatment compared with before treatment p=0.384, after treatment with
Compare p=0.211, p ＞ 0.05 before treatment；
B. control group CD4+CD28+Cell relative value (percentage, %), treatment preceding 32.84 ± 13.48,28.51 in treatment
± 10.50,24.97 ± 9.59 after treatment, Analysis of variance, in treatment compared with before treatment p=0.123, after treatment with treatment
Preceding comparing difference p=0.008, p ＜ 0.05；
C. it between two groups, examines, compares before treatment, in treatment, after treatment, p ＞ 0.05 through independent sample T.
Attached drawing 2-9：A kind of reed mentioned in ancient books Huang group and CD8 in control group therapeutic process+CD28+Cell relative value compares
Note：A. a kind of reed mentioned in ancient books Huang group CD8+CD28+Cell relative value (percentage, %), treatment preceding 13.52 ± 6.82, in treatment
17.36 ± 8.08,23.77 ± 12.90 after treatment, Analysis of variance, in treatment compared with before treatment p=0.117, p ＞ 0.05,
After treatment compared with before treatment p=0.001, p ＜ 0.05；
B. control group CD8+CD28+Cell relative value (percentage, %), treatment preceding 14.40 ± 7.82,19.23 in treatment ±
13.76,18.49 ± 11.64 after treatment, Analysis of variance, in treatment compared with before treatment p=0.113, after treatment with before treatment
Compare p=0.161, p ＞ 0.05；
C. it between two groups, is examined through independent sample T, after relatively comparing p=0.535, treatment in p=0.637, treatment before treating
Compare p=0.093, p ＞ 0.05.
Specific implementation mode
It elaborates to specific implementation mode provided by the invention with reference to embodiment.
It is monarch drug in a prescription, Prunella vulgaris and turmeric clearing heat and eliminating phlegm scattered plot as minister that a kind of reed mentioned in ancient books Huang mixture of the present invention, which is clearing heat and detoxicating using radix scutellariae,
Medicine, the tcm small compound prescription preparation that Radix Astragali QI invigorating righting is adjutant.The work(of clearing heat and detoxicating resolving sputum scattered plot, building up healthful vital energy is played altogether in full side.
The proportioning for a kind of reed mentioned in ancient books Huang mixture that the embodiment of the present invention 1, embodiment 2 use is：2 parts of radix scutellariae, 1 part of Prunella vulgaris, 1 part of turmeric, Radix Astragali 2
Part.
The Randomized controlled clinical study of high-risk diffusivity large B cell lymphoid tumor patient in the treatment of 1 a kind of reed mentioned in ancient books Huang mixture of embodiment
1. materials and methods
1.1 study population
Enter anthology research be untreated our hospital it is initial in high-risk diffusivity large B cell lymphoid tumor patient.Research is adopted
With following screening criteria：
Inclusion criteria
● Gender is unlimited, 18~75 years old age；
● have to comply with the diagnostic criteria of DLBCL.Tissue pathological slice carries out the clear DLBCL's of cellular immunity histochemical analysis
Patient (CD19, CD20 and CD79a are positive)；
● International prognostic index (IPI)：60 years old patient of age ＞, IPI >=2 point；60 years old patient of age ＜, aaIPI
>=1 point；
● medical history information confirms that patient is the first people that cures the disease of untreated；
● Kanofsky scores >=70 points；Or eastern United States tumour cooperation tissue (ECOG) behavioral aspect (Performance
Status, PS)≤2 points of scoring；
● estimated life cycle >=3 month of patient；
Exclusion criteria
● the malignant tumour other than lymthoma is made a definite diagnosis or treated to past attempts；
● existing clinical evidence shows to be converted into lymphoma leukemia；
● immune hemolysis is suffered from, and needs to use glucocorticoid treatment；
● glutamic-pyruvic transaminase (ALT) is more than 3 times of Upper Limit of Normal Value, and glutamic-oxalacetic transaminease (AST) is more than 3 times of Upper Limit of Normal Value,
Total bilirubin (TBIL) be more than 2 times of Upper Limit of Normal Value, 1.5 times of serum creatinine (Scr) ＞ Upper Limit of Normal Value；
● other serious medical illness can impact the research (such as unsteered diabetes, gastric ulcer, Qi Tayan
The heart and lung diseases etc. of weight), judge that power to make decision belongs to researcher；
● infection that is serious or failing control, including HIV infection；
● there are heart disease contraindications not to be resistant to doxorubicin；
● there are the CNS dysfunctions of clinical manifestation；
● the gestational period or nursing period women do not take the Women of Childbearing Age of contraceptives；
● to drug allergy used；
● psychiatric history；
Termination criteria
● there is serious adverse events or complication in subject；
● subject is reluctant continual cure；
● subject's gestation；
● researcher thinks that other reason subjects are unsuitable for continual cure.
Case rejects standard
● violate case inclusion criteria person；
● a trial drug is not used after entering group；
● no any detection record is for evaluation；
● therapeutic process is simultaneously using other chemotherapeutics or biological products for treating lymthoma.
Case falls off
● during experiment, subject's compliance is poor, influences validity and safety evaluatio person；
● serious adverse events, complication and special physiological variation occurs, should not receive to continue experimenter；
● test in the process voluntarily bolter；
● exit experiment, case lost to follow-up because other a variety of causes courses for the treatment of are not finished；
● data is not complete, influences validity and safety evaluatio person.
1.2 research method
1.2.1 research and design
Research carries out the design of testing program using single centre, random, placebo perspective study method.
The patient for meeting screening criteria signs on the basis of understanding and voluntarily agreeing to participate in research and knows through fully informing
Love letter.By 1:1 ratio is randomly divided into 2 groups.
A kind of reed mentioned in ancient books Huang mixture group (QH)：Using a kind of reed mentioned in ancient books Huang mixture+chemotherapeutic treatment；
Control group (Con)：Using traditional Chinese medicine placebo+chemotherapeutic treatment.
Random device：The patient for being included in this research is grouped at random using table of random number method.
1.2.2 therapeutic scheme
I, chemotherapy regimens：Scheme based on CHOP, adds or not plus rituximab.
DLBCL recommends R-CHOP schemes.The First-line chemotherapy Scheme Choice of difference layering patient, foundation《It is thin that China diffuses big B
Born of the same parents' Lymphoma Diagnosis and treatment guidelines (version in 2011)》Suggested design, reference《The diagnosis of ESMO Diffuse Large B-Cell Lymphomas is controlled
It treats and the clinical of follow-up is recommended》And《NCCN oncological clinical practice guides non-Hodgkin lymphoma 2012 editions》.
II, traditional Chinese medical therapeutic programs
Oral traditional Chinese medicine and placebo：
A kind of reed mentioned in ancient books Huang mixture consigned processing is granule, and aluminium bag packaging (is equivalent to crude drug gross weight per pouch containing 4.25 grams of granule
35 grams of amount)
Instructions of taking：1 pouch (4.25 grams) every time, 100-200 milliliters of warm water are drunk after mixing well, it is proposed that interval half after meal
Hour or more take, 2 times a day.
Placebo is made of drug excipient flavoring agent, and appearance, weight, smell, color and luster are similar to drug.Instructions of taking is same
Before.
A kind of reed mentioned in ancient books Huang mixture granule and placebo granulation agent are by Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin's consigned processing, centralized purchasing
Same batch of raw material, according to unified standard time processing prepare, unitizing.
Per 30 days as one therapeutic course, 6 courses for the treatment of are continuously taken, until chemotherapy treatment terminates.Allow occur 2-4 degree during chemotherapy
Withdraw when digestive tract reaction, continues to take after to be restored.
Drug withdrawal indication：Progression of disease or adverse reaction are not resistant to.
III, curative effect mid-stage assessments
3 weeks after 4 chemotherapy treatments of completion, curative effect evaluation is carried out with CT or PET-CT.Adjust therapeutic scheme.
IV, supportive treatments prevent with side effect
In chemotherapy process, when necessary plus with allopurinol and pays attention to alkalization, aquation, prevent tumor lysis syndrome；
Neutrophil leucocyte absolute value (ANC)≤1.0 × 109/ L, Hb ＜ 80g/L, PLT ＜ 20 × 109When/L (or according to tool
Body situation, when researcher feels the need to), granulocyte colony stimulating factor (Granulocyte Colony-can be used respectively
Stimulating Factor, G-CSF), red cells transfusion or blood platelet supportive treatment；
The treatments such as antiemetic, liver protection, acid suppression guarantor's stomach are given as the case may be；
The prophylactic treatment of central nervous system (CNS) infiltration：In high-risk and high-risk patient, especially for 1 with top
Position knot involves outside or the raised patients of LDH, there is the risk that CNS recurs.CNS prophylactic treatments are required for these patients：Testis
Ball and breast benign masses patient should receive CNS prophylactic treatments.
The above treatment should all record.Do not allow to be applied simultaneously to the medicative other drugs of lymthoma, except non-concurrent
Disease needs.
1.2.3 follow-up
After the research is to whole subject's baseline visits, after completing set treatment, that is, enter follow-up.
Follow-up terminates the time：From entering group from first case patient, follow-up event to terminal.
Time：First Year, it is primary per March；Second year, it is primary per June.
Content：Blood routine, routine urinalysis, Liver and kidney function, 2-MG of LDH, β, EKG, superficial lymph knot B ultrasound, abdominal B-scan ultrasonography (liver
Dirty, pancreas, spleen, kidney, posterior peritoneum), rabat (positive side position), electrocardiogram, CT or PET-CT, and corresponding necessary check.
1.2.4 therapeutic evaluation
Curative effect index：
Curative effect index：Complete remission rate (CR) and objective remission rate (Objective Response Rate,
ORR).Standard is formulated according to WHO in 1981 and carries out clinical assessment, is divided into complete incidence graph (CR), part is alleviated (PR), stablized
(SD), it recurs or is in progress (PD).
Secondary efficacy index：
● functional status cassette scores (Kanofsky).
● safety indexes：Blood routine, routine urinalysis, hepatic and renal function and electrocardiogram etc..
The standard of curative effect evaluation：
● the guide and international association in 2007 that international working group in 1999 delivers can be used in evaluation criterion the effect of lymthoma
It adjusts and plans revised guide.
● objective remission rate (Objective response rate, ORR)：CR+PR.ORR is defined as Intentionality treatment people
Reach subject's percentage of CR+PR in group (Intention-To-Treat, ITT) after treatment.Calculation formula：ORR=(CR+
PR total case load × 100% of)/ITT.
● the diminution for the enlarged lymph node volume that CT scan measures and bone marrow smear and the marrow of biopsy determination are invaded journey
Degree.Curative effect reaction be divided into complete incidence graph (complete remission, CR), not really
Fixed complete incidence graph (unconfirmed CR, CRu), part are alleviated (partial remission, PR), are stablized
(stable disease, SD), recurrence or progress (progression disease, PD).18-fluorodeoxyglucose positive electrons
Emission tomography computer scanning (FDG-PET/CT), due to PET/CT can determine remaining lump whether partly alleviate or it is complete
Alleviate, therefore revised standard reversal CRu, is only divided into CR, PR, SD, PD.
● Karnofsky functional status scoring (Cattell, KPS, percentage) standard.It is to improve to increase by 10 points of persons, is reduced super
10 points are crossed to deteriorate, increases or decreases and is less than 10 points to stablize.
● evaluation criterion of the reference common adverse reactions event evaluation standard (NCI CTCAE) 4.03 editions about adverse reaction
Evaluation.
1.2.5 statistical analysis
All clinical datas input computer, professional's data inputting, by ITT (intention to after collection
Treat, ITT) analysis principle, row complete analysis collection (FAS) analysis.The specific method selection of statistical analysis is as follows：Efficacy data point
Analyse expressed as a percentage, two groups are compared with rank sum test (Mann-Whitney U examine), and accurately examined using Fisher's
Method detects two groups of statistical significance.The grouped datas such as adverse events will be showed by list of frequency, and quantitative data is (strictly according to the facts
Test room inspection) it grouped data will be converted into according to NCIC CTC hierarchy systems will analyze.
● measurement data：The pretherapy and post-treatment mean of each group compares with paired t-test, and mean is compared to each other with only between two groups
Vertical sample t-test selects P values according to homogeneity test of variance result, does not meet the nonparametric that normal distribution person then uses order conversion
It examines.
● enumeration data：Use χ2It examines.
● orderly ranked data：With Wilcoxon rank sum tests.
● there are the standard of statistical significance, 0.05 differences of P ＜ in specification test level α=0.05 with 0.05 for two-sided test
It is statistically significant.
After using SPSS17.0 statistical packages carry out statistical procedures.
2. result
2.1 case features
70 standard compliant patients are shared in September, 2014, through screening in October, 2013 enter group, every group each 35,
Middle a kind of reed mentioned in ancient books Huang mixture group 2 is removed because never taking Chinese medicine, control group totally 3 make rejecting processing (2 for the first time enter group reevaluate
AaIPI=0 point, 1 enter group for the first time after merge Severe Pulmonary Infection, KPS ＜ 70).Without the case that falls off.Finally may be used by ITT principles
It is 65 total to count case, derives from Ruijin Hospital hematology ward.
Age is 23 years old minimum, 73 years old maximum, average 52.05 ± 10.84 years old (a kind of reed mentioned in ancient books Huang group 52.03 ± 12.13 years old, control group
52.06 ± 13.96 years old), the median age 55 years old.Wherein a kind of reed mentioned in ancient books Huang group 33, control group 32.Male 38 (a kind of reed mentioned in ancient books Huang group 18, it is right
According to group 20) account for 58.4%；Women 27 (a kind of reed mentioned in ancient books Huang group 15, control group 12) accounts for 41.6%.In addition to control group hepatitis B surface is anti-
Antigen positive hybridomas number of cases is outer (p ＜ 0.05) on the high side, remaining essential characteristics of two groups of cases for example gender, the age, weight, body surface area,
ECOG muscle power situation, blood pressure, pulse frequency etc. basis equalization.Two groups of cases be the CD20 that just controls it is positive diffuse large B cell
Type NHL patient, neoplasm staging (Ann Arbor methods), molecule parting, clinical manifestation, some features of tumour and the world are pre-
Index (IPI) scoring afterwards is compared basis equalization between two groups of patients, and there was no significant difference.
2.2 therapeutic evaluation
All 65 patients complete chemotherapy, and using R-CHOP schemes 64, only QH groups 1 are because of the economic cause selection side CHOP
The utilization rate of case, Rituximab has reached 98.5% (64/65).4 course for the treatment of chemotherapy 1 (QH groups) is completed, 6 course for the treatment of R-are completed
CHOP schemes 8 (every group each 4), complete 8 courses for the treatment of (6 × R-CHOP+2 × R) 56 (every group each 28), and two groups of chemotherapy are completed
Situation indifference.
2.2.1. treatment mid-term and final curative effect evaluation
Mid-stage assessment is carried out to curative effect after completing 4 course for the treatment of chemotherapy, is as a result shown：Reach CR 45 (QH groups 27, control
Group 18), reach PR 19 (QH groups 6, control group 13), progression of disease PD 1 appears in control group, which uses instead
RICE schemes reach CR to curative effect when final period assessment.QH groups and control group mid-stage assessment CR rates be respectively 81.8% (27/33) and
56.3% (18/32)；ORR rates are respectively 100% (33/33) and 96.9% (31/32).General curative effect, through Mann-Whitney
U is examined, Z=-2.258, accurate conspicuousness (bilateral) P=0.028.Two groups of mid-stage assessment curative effects compare, and difference has statistics meaning
Justice, P ＜ 0.05.Refer to table 1-1, Fig. 1-1.
1-1 a kind of reed mentioned in ancient books Huang group of table % (n) compared with control group mid-term effects
Note：* a kind of reed mentioned in ancient books Huang group and control group mid-term general curative effect compare, and are examined through Mann-Whitney U, Z=-2.258, essence
True conspicuousness (bilateral) P=0.028, P ＜ 0.05.
Final curative effect evaluation is carried out after completing 8 course for the treatment of chemotherapy, is as a result shown：Reach CR 55 (QH groups 31, control group
24), reach PR 6 (QH groups 1, control group 5), progression of disease PD4 (QH groups 1, control group 3).Two groups of total CR
Rate 84.6%, wherein QH groups 93.9% (31/33), control group 75% (24/32).Two groups of total ORR rates 93.8%, wherein QH groups
97.0% (32/33), control group 90.6% (29/32).General curative effect is examined, Z=-2.072, gradually through Mann-Whitney U
Nearly conspicuousness (bilateral) P=0.038, two groups of final period assessment curative effects compare, and asymptotic significance test reaches statistical significance, P ＜
0.05.Refer to table 1-2, Fig. 1-2.
1-2 a kind of reed mentioned in ancient books Huang group of table % (n) compared with control group final period curative effect
Note：* compared with control group final period general curative effect, Mann-Whitney U are examined a kind of reed mentioned in ancient books Huang group, and Z=-2.072 is asymptotic
Conspicuousness (bilateral) P=0.038, P ＜ 0.05.
Two groups of CR rates compare, mid-term effects, through chi-square analysis, χ2=4.986, p=0.033, p ＜ 0.05, difference has system
Meter learns meaning；Final curative effect, through chi-square analysis, χ2=4.477, p=0.044, difference is statistically significant, p ＜ 0.05.It refers to
Fig. 1-3.
The result shows that a kind of reed mentioned in ancient books Huang mixture group * obtains CR earlier compared with control group, reach statistical significance, and final assessment disease
The case load that is in progress is less than control group；Overall relief rate mid-stage assessment a kind of reed mentioned in ancient books Huang group is better than control group, reaches statistical significance, P ＜
0.05；Final a kind of reed mentioned in ancient books Huang group advantage is very close to statistical significance, p=0.053.
2.2.2. the effect of cassette functional status scoring layering, is analyzed
In cassette functional status scoring (Kanofsky, KPS) 70 points of 34 patients (a kind of reed mentioned in ancient books Huang group 15, control group 19),
28 acquirement CR (a kind of reed mentioned in ancient books Huang group 14, control group 14), 93.3%/73.7%；In KPS80 points of 15 patients (a kind of reed mentioned in ancient books Huang group 8,
Control group 7), 13 acquirement CR (a kind of reed mentioned in ancient books Huang group 8, control group 5), 100%/71.4%；KPS90 points 12 patient's (a kind of reed mentioned in ancient books
Huang group 7, control group 5) in 10 obtain CR (a kind of reed mentioned in ancient books Huang group 6, control group 4), 85.7%/83.3%；KPS 100 divides 4
In example patient (a kind of reed mentioned in ancient books Huang group 3, control group 1), CR is entirely reached.A kind of reed mentioned in ancient books Huang group CR in the patient of KPS poor (70 and 80 points)
Rate 95.7% (22/23) is higher than control group 73.1% (19/26), through Chi-square Test, χ2=4.553, p=0.033, difference have system
Meter learns meaning (P ＜ 0.05).Refer to table 1-3, Fig. 1-4.
1-3 a kind of reed mentioned in ancient books Huang group of table % (n) compared with the CR rates that control group Kanofsky scores
The result shows that a kind of reed mentioned in ancient books Huang group significantly improves the CR rates of the patient of KPS poor (70 and 80 points), reach statistical significance P
＜ 0.05.
2.2.3 the degree of cassette functional status scoring variation
Further according to the degree of pretherapy and post-treatment KPS variations, Different therapeutical effect is counted.It is to improve to increase by 10 points of persons, is reduced super
Cross 10 points for deteriorate, increase or decrease≤10 points for stablize.As a result it shows：The pretherapy and post-treatment KPS of a kind of reed mentioned in ancient books Huang group improves 10
(30.3%), stablize 21 (63.6%), deteriorate 2 (6.1%)；Control group be respectively 3 (9.4%), 22 (68.8%),
1 (21.9%).Through Chi-square Test, χ2=6.556, p=0.037, difference are statistically significant.Refer to Fig. 1-5.
It is significantly better than control group the result shows that totally improving after the KPS treatments of a kind of reed mentioned in ancient books Huang group, reaches statistical significance, P ＜
0.05。
2.3 safety evaluation
There are about 30% patients, and slight infusion correlated response to occur when being transfused Rituximab for the first time, including generate heat,
Shiver with cold, chilly, oedema etc., general symptom is slight (NCI-CTC l or 2 grades), by slowing down transfusion speed and preventive use
Methylprednisolone can solve.
Overall adverse reaction rate a kind of reed mentioned in ancient books Huang group is 66.7% (22/33), and control group is 78.1% (25/32), two groups of ratios
Compared with no significant difference (P=0.110).147 person-times of adverse reactions occur altogether for a kind of reed mentioned in ancient books Huang group, and control group occurs between 198 person-times, two groups
Compare, through Chi-square Test, χ2=12.755, p=0.000, difference is significant, is shown in Table 1-4.
Neutrophilic granulocytopenia, anaemia and decrease of platelet are most commonly seen in two groups of haematics toxicities.A kind of reed mentioned in ancient books Huang group neutrality grain
Leukopenia incidence accounts for 48.5% (16/33), and control group is 65.6% (21/32)；Anaemia incidence is respectively a kind of reed mentioned in ancient books Huang group
45.5% (15/33) and control group 56.3% (18/32)；Decrease of platelet incidence be respectively a kind of reed mentioned in ancient books Huang group 27.3% (9/33) and
Control group 31.3% (10/32), individual event is more without difference.Overall blood toxicity a kind of reed mentioned in ancient books Huang group occurs 40 person-times, control group
Occur 49 person-times, through Chi-square Test, χ2=2.222, p=0.136, a kind of reed mentioned in ancient books Huang group are less than control group, but not up to statistically significant
Property.
Weak (67.7%), nausea and vomiting (58.5%), loss of appetite (41.5%) occur in two groups of non-blood toxicity
It is most commonly seen, remaining be followed successively by alopecia (29.2%), weight loss (29.2%), catarrh (27.7%), constipation (27.7%),
Diarrhea (15.4%), abdominal pain (15.4%), blood urine (15.4%), albuminuria (6.2%).Wherein weak incidence is respectively a kind of reed mentioned in ancient books Huang
57.6% (19/33) of group and control group 78.1% (25/32), two groups are compared P=0.077；Catarrh incidence is respectively a kind of reed mentioned in ancient books Huang
18.2% (6/33) of group and control group 37.5% (12/32), two groups are compared P=0.082, close to statistical significance, remainder
Mesh comparing difference is not notable.Overall non-blood toxicity a kind of reed mentioned in ancient books Huang group occurs 97 person-times, and control group occurs 133 person-times, through card side
It examines, χ2=9.641, p=0.002, a kind of reed mentioned in ancient books Huang group are substantially less than control group, have statistics to show meaning.
A kind of reed mentioned in ancient books Huang group liver function damage has 4, is 1-2 grade, control group 6, and it is III grade to have 3, through liver protection supportive treatment
Restore normal, chemotherapy is not impacted.Control group has 5 HBsAg positives and 2 HBV-DNA ＞ 103Chronic Hepatitis B,
It gives Lamy stationary slice, dosing adefovir dipivoxil tablets etc. and continues antiviral therapy stable disease, do not find dysfunction of liver fluctuation and virus
It replicates and increases situation.
A kind of reed mentioned in ancient books Huang group occurs symptom uncomfortable in chest and changes 1 with ECG T wave, and patient previously has hypertension history, through decompression etc. pair
Disease treats remission；Similar cardiovascular event 2 occurs for control group, is all happened at the basic cardiovascular and cerebrovascular disease of previously merging and suffers from
Person, Cardiac ultrasound Left Ventricular Ejection Fraction is in normal range (NR).
Do not find that serum creatinine increases renal impairment case for two groups in research.
Occur 7 in chemotherapy process altogether and merge pulmonary infection case (a kind of reed mentioned in ancient books Huang group 2, control group 5), through actively anti-infective
Treatment, final inflammation are controlled, and wherein Severe Pulmonary Infection merging fungal infection occurs for control group 1, leads to chemotherapy cycles
It is forced to extend 20 days.
Occur 3-4 grades of 15 person-times of hematotoxicities in chemotherapy process altogether, wherein 4 person-times of a kind of reed mentioned in ancient books Huang group (10%, 4/40 person-time), right
According to group 11 person-times (22.4%, 11/49 person-time), two groups are compared, through Chi-square Test, p=0.182, not up to statistical significance.Altogether
3-4 grades of 10 person-times of non-blood toxicity occur, for weak (2), fever (1), nausea and vomiting (1), constipation (1), mucous membrane
Alopecia 1 only occurs for scorching (2), alopecia (3), wherein a kind of reed mentioned in ancient books Huang group, and two groups are compared, through Chi-square Test, p=0.036.As a result table
Bright, 3-4 grades of non-blood toxicity of a kind of reed mentioned in ancient books Huang group are substantially less than control group, there is statistical significant difference (P ＜ 0.05).It is shown in Table 1-4.
Two groups occur without serious adverse events.
1-4. Common Toxicity of table reaction incidence compares (n, %)
Note：* a kind of reed mentioned in ancient books Huang group is compared with control group non-blood toxicity, through Chi-square Test, χ2=9.641, p=0.002；3-4 grades
Non-blood toxicity, p=0.036, P ＜ 0.05.
The result shows that a kind of reed mentioned in ancient books Huang group is all and 3-4 grades of non-blood toxicity are significantly less than control group, P ＜ 0.05, difference has system
Meter learns meaning.3-4 grades of toxicity incidences are low in therapeutic process, and overall tolerability is good.
3. brief summary
High-risk DLBCL patient during the joint R-CHOP chemotherapy regimens treatment of a kind of reed mentioned in ancient books Huang mixture is initial, phase is treated with simple R-CHOP
Than mid-term effects CR rates 81.8%vs56.3%, ORR100%vs96.9%；Final curative effect CR rate 93.9%vs75%,
ORR96.9%vs90.6%.Combination therapy obtains complete incidence graph earlier, and curative effect is better than chemotherapy.
A kind of reed mentioned in ancient books Huang mixture improves the CR rates (95.7%vs 73.1%) of the poor patients of KPS.
A kind of reed mentioned in ancient books Huang mixture alleviates the toxicity of chemotherapy, especially non-blood toxicity.
Influence of the 2 a kind of reed mentioned in ancient books Huang mixture of embodiment to Diffuse Large B-Cell Lymphoma patient immune function in chemotherapy process
1. materials and methods
1.1 material
Flow cytometer (Flow Cytometry, FCM)：The FACS of U.S. company BD (Becton Dickinson) production
CantoTMII, reagent is the CD series that B-D companies of the U.S. produce.
800 immunochemistry system specific protein analyzers and matched reagent, U.S.'s Beckman
(BECKMAN/COULER) company.
1.2 research method
T cell subsets counts are detected using monoclonal antibody fluorescent marker and Flow Cytometry.
Blood preparation：Blood preparation (peripheral blood) requires anti-freezing, EDTA or anticoagulant heparin；Volume 2-4mL, 4 DEG C
Refrigerate inspection.
1.3 statistical procedures
Inspection result is with mean ± standard deviationIt indicates, the comparison of mean uses before and after treatment between two groups or in group
T is examined；Multisample measurement data compares using ANOVA one-way analysis of variances, and variance is examined with LSD together, and heterogeneity of variance is used
Dunnett T3 are examined.It is inspection level with α=0.05.All of above inspection bilateral p ＜ 0.05 think that difference has statistics meaning
Justice.Correlation statistical analysis is completed by 17 softwares of SPSS.Chart production Microsoft Excel2007 and Microsoft
PowerPoint2007 softwares are completed.
2. the variation of T cell subgroup CD3+, CD4+, CD8+ cell during 2.1 two groups of chemotherapy of result
The T lymphocyte subsets sampled data of this research has partial data before all being treated in 65 patients
63 (a kind of reed mentioned in ancient books Huang group 33, control groups 30) have partial data 60 (a kind of reed mentioned in ancient books Huang group 33, control (after 4 period chemotherapy) in treatment
Group 27), there is partial data 63 (a kind of reed mentioned in ancient books Huang group 31, control group 32) after treatment (after the completion of 6-8 period chemotherapy).
This result of study is shown：Full group CD3+The phase is decreased obviously T cell absolute counting in the treatment, and difference has system
Meter learns meaning, p ＜ 0.05；Though being gone up after the treatment, it is more still in bright before level, with treatment that cannot still reach before treating
It is aobvious to decline, there are statistically-significant difference, p ＜ 0.05.CD3+It is showed in cell relative value (%) treatment and significantly rises and treat
Slow downward trend afterwards, in treatment, treatment after compared with before treatment, difference is statistically significant, p ＜ 0.05；Treatment neutralizes
Not statistically significant, p ＞ 0.05 are compared after treatment.A kind of reed mentioned in ancient books Huang group CD3+The situation of change of T cell is similar to organizing entirely, and control group
CD3+T cell absolute counting declines that degree is very close but not up to statistical significance.
Two comparison among groups, CD3 between two groups+(%) and absolute counting compare before treatment, in treatment, after treatment, through independent sample
This T is examined, and difference is not statistically significant, p ＞ 0.05.2-1,2-2 are shown in Table, Fig. 2-1,2-2.
2-1 a kind of reed mentioned in ancient books Huang group of table and the pretherapy and post-treatment T cell subgroup CD3 of control group+、CD4+、CD8+Relative value compares
Note：#：It is preceding than p ＜ 0.05 with treatment after 4 courses for the treatment of in group；*：It is preceding than p ＜ 0.05 with treatment after 6-8 courses for the treatment of in group；
○：Than p ＜ 0.05 (the same below) between two groups
1-2 a kind of reed mentioned in ancient books Huang group of table and the pretherapy and post-treatment T cell subgroup CD3 of control group+、CD4+、CD8+Absolute counting compares
Note：Same upper table
Full group CD3+CD4+T cell absolute counting being remarkably decreased after phase and treatment in the treatment in progressive, two groups of presentations
Identical downward trend, difference is statistically significant, p ＜ 0.05；Two comparison among groups, no significant difference, p ＞ 0.05.CD3+CD4+T cell relative value (%) treats mid-term and declines unobvious, declines obviously compared with before treatment after treatment, difference has statistics
Meaning, p ＜ 0.05, wherein the situation of change of control group is similar to organizing entirely, and a kind of reed mentioned in ancient books Huang group CD3+CD4+T cell relative value declines not
Obviously, difference is not up to statistical significance, p ＞ 0.05.
Two groups of CD3+CD4+Compare before T cell relative value and absolute counting treatment, in treatment, after treatment, through independent sample T
It examines, difference is not statistically significant, p ＞ 0.05.See Fig. 2-3,2-4.
Full group CD3+CD8+T cell absolute counting, in treatment, treatment after compared with before treatment, no significant difference,
Two comparison among groups no significant differences, p ＞ 0.05.CD3+CD8+T cell relative value compares in treatment, after treatment with before treatment
Relatively rise in progressive, difference is statistically significant, p ＜ 0.05.
Two groups of CD3+CD8+Compare before the treatment of T cell absolute counting, in treatment, after treatment, difference is examined through independent sample T
It is not statistically significant, p ＞ 0.05；Two groups of CD3+CD8+In the treatment of T cell relative value compared with before treatment, examined through independent sample T
It tests, difference is not statistically significant, p ＞ 0.05；After treatment compared with before treatment, p=0.035, difference is statistically significant, p
＜ 0.05.See Fig. 2-5,2-6.
Full group CD4+/CD8+Cell absolute counting ratio being remarkably decreased in the treatment, after treatment in progressive, and two groups be in
Existing identical downward trend, difference is statistically significant, p ＜ 0.05.
Two groups of CD4+/CD8+Compare before cell ratio treatment, in treatment, after treatment, is examined without statistics through independent sample T
Learn meaning, p ＞ 0.05.Control group CD4 after the treatment+/CD8+Ratio=0.98 (＜ 1), and a kind of reed mentioned in ancient books Huang group ratio=1.12 (＞ 1).
See Fig. 2-7.
T cell subgroup CD4 during 2.2 two groups of chemotherapy+CD28+、CD8+CD28+The variation of T cell ratio
Full group CD4+CD28+Cell relative value (percentage, %), the phase declines unobvious in the treatment, and declines after treating aobvious
It writes, difference is statistically significant, p ＜ 0.05.Decline difference is not notable compared with before treatment in the treatment of a kind of reed mentioned in ancient books Huang group, after treatment, p ＞
0.05；Control group treats mid-term and declines unobvious, p ＞ 0.05；And decline after treating significantly, difference is statistically significant, p ＜
0.05.Two comparison among groups, no significant difference.
Two groups of CD4+CD28+Cell relative value compares before treatment, in treatment, after treatment, examines difference equal through independent sample T
It is not statistically significant, p ＞ 0.05.Fig. 2-8.
Full group CD8+CD28+Cell relative value (percentage, %), apparent rising, difference have system in the treatment and after treatment
Meter learns meaning, p ＜ 0.05.The treatment mid-term rising of a kind of reed mentioned in ancient books Huang group is not notable, and rises significantly compared with before treatment after treating, and difference has
Statistical significance, p ＜ 0.05；Rise unobvious in control group treatment and after treatment, difference is not up to statistical significance, p ＞
0.05。
Two groups of CD8+CD28+Cell relative value compares before treatment, in treatment, after treatment, examines difference equal through independent sample T
It is not statistically significant, p ＞ 0.05.Fig. 2-9.
Brief summary
There is the significant change of T cell subgroup in R-CHOP chemotherapy process in DLBCL patient, after being mainly shown as chemotherapy
CD4+The inhibition of cell and its subgroup.
A kind of reed mentioned in ancient books Huang mixture is to CD3+CD4+T cell, CD4+CD28+Cell has protective effect, improves CD4+/CD8+Cell ratio.
3 Chinese medicine composition of embodiment
1 part of radix scutellariae, 1.5 parts of Prunella vulgaris, 0.5 part of turmeric, 3 parts of Radix Astragali
4 Chinese medicine composition of embodiment
1.8 parts of radix scutellariae, 1.1 parts of Prunella vulgaris, 0.9 part of turmeric, 2.2 parts of Radix Astragali
5 Chinese medicine composition of embodiment
2 parts of radix scutellariae, 1 part of Prunella vulgaris, 1 part of turmeric, 2 parts of Radix Astragali
6 Chinese medicine composition of embodiment
2.2 parts of radix scutellariae, 0.9 part of Prunella vulgaris, 1.1 parts of turmeric, 1.8 parts of Radix Astragali
7 Chinese medicine composition of embodiment
3 parts of radix scutellariae, 0.5 part of Prunella vulgaris, 1.5 parts of turmeric, 1 part of Radix Astragali
The preparation of 8 Chinese medicine composition of embodiment
The pharmaceutical dosage form that the Chinese medicine composition of embodiment 3-8 is prepared according to conventional formulation means, such as granule etc..
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, under the premise of not departing from the method for the present invention, can also make several improvement and supplement, these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (6)
1. a kind of Chinese medicine composition for treating lymthoma, which is characterized in that the Chinese medicine composition by following parts by weight original
Material medicine is made：2 parts of radix scutellariae, 1 part of Prunella vulgaris, 1 part of turmeric, 2 parts of Radix Astragali.
2. Chinese medicine composition according to claim 1, which is characterized in that the Chinese medicine composition and the chemotherapy sides R-CHOP
Case or CHOP chemotherapy regimen combination therapies.
3. application of the Chinese medicine composition according to claim 1 in the drug for preparing treatment lymthoma.
4. application according to claim 3, which is characterized in that the lymthoma is non-Hodgkin lymphoma.
5. application according to claim 3, which is characterized in that the lymthoma is B cell lymphoma.
6. application according to claim 4, which is characterized in that the lymthoma is diffusivity large B cell lymphoid tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510364639.2A CN104940823B (en) | 2015-06-26 | 2015-06-26 | Scutellaria baicalensis-scutellaria baicalensis mixture for treating B cell lymphoma and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510364639.2A CN104940823B (en) | 2015-06-26 | 2015-06-26 | Scutellaria baicalensis-scutellaria baicalensis mixture for treating B cell lymphoma and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104940823A CN104940823A (en) | 2015-09-30 |
| CN104940823B true CN104940823B (en) | 2018-08-21 |
Family
ID=54156246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510364639.2A Expired - Fee Related CN104940823B (en) | 2015-06-26 | 2015-06-26 | Scutellaria baicalensis-scutellaria baicalensis mixture for treating B cell lymphoma and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104940823B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108802383B (en) * | 2018-06-21 | 2021-05-11 | 首都医科大学附属北京地坛医院 | Hepatitis B three-small positive low replication period pregnancy period reactivation monitoring equipment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188011A (en) * | 1997-01-13 | 1998-07-22 | 任玉让 | Chinese herbal medicine composition for curing malignant lymphoma |
-
2015
- 2015-06-26 CN CN201510364639.2A patent/CN104940823B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188011A (en) * | 1997-01-13 | 1998-07-22 | 任玉让 | Chinese herbal medicine composition for curing malignant lymphoma |
Non-Patent Citations (5)
| Title |
|---|
| 夏枯草对淋巴瘤细胞增殖的影响;张明智 等;《医药论坛杂志》;20070131;第28卷(第1期);第54-55页 * |
| 姜黄素诱导Raji、HL-60和K562组蛋白乙酰化的研究;王妍 等;《中国药理学通报》;20060228;第22卷(第2期);第164-167页 * |
| 赵树珍主任医师诊治恶性淋巴瘤经验;孙大兴 等;《浙江中医学院学报》;19990630;第23卷(第3期);第45-46页 * |
| 黄芩苷诱导Burkitt淋巴瘤细胞凋亡的初步研究;肖丹 等;《内科理论与实践》;20111231;第6卷(第1期);第52-55页 * |
| 黄芪对荷瘤小鼠化疗后免疫功能的影响;刘倩倩;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20131115(第11期);E057-30，第28页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104940823A (en) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102670944B (en) | A kind of compound Chinese medicinal preparation for the treatment of ovarian cancer and preparation method thereof | |
| Xiao et al. | Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non–small-cell lung carcinoma: A systematic review and meta-analysis of 54 randomized controlled trials | |
| CN103055258B (en) | A kind of regulate and control the medicine of liver regeneration and control prece thereof | |
| CN102727687B (en) | Medicine treating chronic fatigue syndrome and its application | |
| CN104940823B (en) | Scutellaria baicalensis-scutellaria baicalensis mixture for treating B cell lymphoma and application thereof | |
| CN110354239B (en) | Stomach harmonizing and vomiting stopping cream formula and preparation method and application thereof | |
| Lahans | Integrating conventional and Chinese medicine in cancer care: A clinical guide | |
| CN100381164C (en) | Medicine for treating radiation diseases | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN106362092B (en) | A kind of Yiqi Huoxue TCM composition for treating liver fibrosis | |
| CN102188592A (en) | Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof | |
| CN115105576B (en) | Traditional Chinese medicine composition for treating ovarian cancer, traditional Chinese medicine preparation and application thereof | |
| CN108236672A (en) | A kind of drug for treating primary Sjogren's syndrome and preparation method thereof | |
| CN116407595B (en) | Traditional Chinese medicine composition for treating triple negative breast cancer, traditional Chinese medicine preparation and application thereof | |
| CN102327462B (en) | Traditional Chinese medicine for treating qi and blood insufficiency asthenia diseases of leukemia patients after chemotherapy and method for preparing traditional Chinese medicine preparations | |
| CN103877509B (en) | A kind of medicine and its preparation method treating leukemia | |
| CN103989779B (en) | A kind of Radix Angelicae Sinensis CHENGQI TANG merges lithium carbonate group compound and application thereof | |
| Amelliya et al. | A Review: Plants That Have Activities As Anti-Anemia | |
| CN111437362B (en) | Traditional Chinese medicine composition for adjuvant treatment of middle and late intestinal cancer and preparation method and application thereof | |
| de Almeida-Neto et al. | Survival among children and adults treated with granulocyte transfusions: Twenty years’ experience at a Brazilian blood center | |
| CN101721612A (en) | Chinese medicinal composition for raising leucocytes and preparation method and application thereof | |
| CN106334027B (en) | The Chinese medicine composition for treating hepatitis B relevant acute-on-chronic liver failure early period | |
| CN104998135B (en) | A kind of Chinese medicine composition of soothing the liver dissipating bind treatment liver cancer and its application | |
| Luo et al. | The Treatment of Chinese Herbal Prescription in a 43 Year-old Woman with Sjogren Syndrome: A Case Report | |
| Nawaz et al. | Oral versus Parenteral Iron Supplements: Which is better in Postpartum Iron Deficiency Anemia? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180821 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |